125
Views
10
CrossRef citations to date
0
Altmetric
BIOMARKERS

Comparison of Bronchial Hyperresponsiveness to Methacholine and Adenosine and Airway Inflammation Markers in Patients with Suspected Asthma

, M.D., , M.D., , M.D>, , M.D. & , M.D., Ph.D.
Pages 335-340 | Published online: 19 Apr 2011

References

  • Cockcroft DW. Direct challenge tests: airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010; 138(Suppl. 2):18S–24S.
  • Anderson SD. Indirect challenge tests: airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010; 138(Suppl. 2):25S–30S.
  • Enright PL, Lebowitz MD, Cockroft DW. Physiologic measures: pulmonary function tests. Asthma outcome. Am J Respir Crit Care Med 1994; 149:S9–S18.
  • Avital A, Springer C, Bar-Yishay E, Godfrey S. Adenosine, methacholine, and exercise challenges in children with asthma or paediatric chronic obstructive pulmonary disease. Thorax 1995; 50:511–516.
  • Fowler SJ, Dempsey OJ, Sims EJ, Lipworth BJ. Screening for bronchial hyperresponsiveness using methacholine and adenosine monophosphate. Relationship to asthma severity and beta(2)-receptor genotype. Am J Respir Crit Care Med 2000; 162:1318–1322.
  • Pedrosa M, Barranco P, Caminoa M, Botello MD, Quirce S. Comparison of methacholine and adenosine inhalation challenge in patients with suspected asthma. J Asthma 2009; 46:773–776.
  • Ribeiro M, Pereira CA, Nery LE, Beppu OS, Silva CO. Methacholine vs adenosine on intra and extrathoracic airway hyperresponsiveness in patients with cough variant asthma. Allergy 2008; 63:527–532.
  • Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161:309–329.
  • Pepys J. Skin tests. Br J Hosp Med 1984; 32:120–124.
  • Sastre J, Fernandez-Nieto M, Novalbos A, De Las Heras M, Cuesta J, Quirce S. Need for monitoring nonspecific bronchial hyperresponsiveness before and after isocyanate inhalation challenge. Chest 2003; 123:1276–1279.
  • Fardon TC, Fardon EJ, Hodge MR, Lipworth BJ. Comparative cutoff points for adenosine monophosphate and methacholine challenge testing. Ann Allergy Asthma Immunol 2004; 93:365–372.
  • Sastre B, Fernández-Nieto M, Mollá R, López E, Lahoz C, Sastre J, del Pozo V, Quirce S. Increased prostaglandin E2 levels in the airway of patients with eosinophilic bronchitis. Allergy 2008; 63:58–66.
  • Joos GF, O’Connor B, Anderson SD, Chung F, Cockcroft B, Dahlén B, DiMaria G, Foresi A, Hargreave FE, Holgate ST, Inman M, Lötvall J, Magnussen H, Polosa R, Postma DS, Riedler J. ERS Task Force. Indirect airway challenges: statement of the European Respiratory Society. Eur Respir J 2003; 21:1050–1068.
  • Dickinson JW, Whyte GP, McConnell AK, Harries MG. Impact of changes in the IOC-MC asthma criteria: a British perspective. Thorax 2005; 60:629–632.
  • Cockcroft DW, Davis BE. The bronchoprotective effect of inhaling methacholine by using total lung capacity inspirations has a marked influence on the interpretation of the test result. J Allergy Clin Immunol 2006; 117:1244–1248.
  • Prieto L, Reig I, Rojas R, Ferrer A, Domenech J. The effect of challenge method on sensitivity and reactivity to adenosine 5’-monophosphate in subjects with suspected asthma. Chest 2006; 130:1448–1453.
  • Andregnette-Roscigno V, Fernández-Nieto M, Del Potro MG, Aguado E, Sastre J. Methacholine is more sensitive than mannitol for evaluation of bronchial hyperresponsiveness in children with asthma. J Allergy Clin Immunol 2010; 126:869–871.
  • Anderson SD, Charlton B, Weiler JM, Nichols S, Spector SL, Pearlman DS, A305 Study Group. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. Respir Res 2009; 23(10):4.
  • Prieto L, Gutierrez V, Uixera S. Exhaled nitric oxide and bronchial responsiveness to adenosine 5-monophosphate in subjects with allergic rhinitis. Chest 2002; 121:1853–1859.
  • van Den Toorn LM, Prins JB, Overbeek SE, Hoogsteden HC, de Jongste JC. Adolescents in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and bronchial hyperresponsiveness. Am J Respir Crit Care Med 2000; 162:953–957.
  • Van Den Berge M, Meijer RJ, Kerstjens HA, de Reus DM, Koëter GH, Kauffman HF, Postma DS. PC20 adenosine 5′-monophosphate is more closely associated with airway inflammation in asthma than PC20 methacholine. Am J Respir Crit Care Med 2001; 163:1546–1550.
  • Van den Berge M, Kerstjens HA, de Reus DM, Koëter GH, Kauffman HF, Postma DS. Provocation with adenosine 5′-monophosphate, but not methacholine, induces sputum eosinophilia. Clin Exp Allergy 2004; 34:71–76.
  • Volbeda F, ten Hacken NH, Lodewijk ME, Dijkstra A, Hylkema MN, Broekema M, Timens W, Postma DS. Can AMP induce sputum eosinophils even in subjects with complete asthma remission? Respir Res 2010; 11:106.
  • Wilson AM, Duong M, Pratt B, Dolovich M, O’Byrne PM. Anti-inflammatory effects of once daily low dose inhaled ciclesonide in mild to moderate asthmatics patients. Allergy 2006; 67:537–542.
  • Green RH, Brightling CE, McKenna S, Hargadon B, Neale N, Parker D, Ruse C, Hall IP, Pavord ID. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. Eur Respir J 2006; 27:1144–1151.
  • Choi SH, Kim DK, Yu J, Yoo Y, Koh YY. Bronchial responsiveness to methacholine and adenosine 5′-monophosphate in young children with asthma: their relationship with blood eosinophils and serum eosinophilic cationic protein. Allergy 2007; 62:1119–1124.
  • Bakirtas A, Turktas I. Determinants of airway responsiveness to adenosine 5′- monophosphate in school-age children with asthma. Pediatr Pulmonol 2006; 41:515–521.
  • Bakirtas A, Turktas I. Airway hyper-responsiveness to adenosine 5′-monophosphate in preschool-age children with asthma. Pediatr Allergy Immunol 2006; 17:428–434.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.